SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ:GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses to submit your losses now. The upcoming lead plain…
Wall Street's Reassessment of Grail: How Analyst Expectations Built on Positive NHS-Galleri Representations Collapsed Alongside GRAL's $51.32 Per-Share DeclineNEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt tracks the evolution of Wall Street analyst opinion on Grail, Inc. (NASDAQ:GRAL) following…
From Optimism to Disillusionment: How Investor Sentiment in Grail Shifted as NHS-Galleri Confidence Crumbled, Costing Shareholders $51.32 Per ShareNEW YORK, July 23, 2026 /PRNewswire/ -- SueWallSt provides context on investor sentiment surrounding Grail, Inc. (NASDAQ:GRAL) and a pending securities…
SAN DIEGO, July 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of GRAIL, Inc. (NASDAQ:GRAL) common stock between May 13, 2025 and February 19, 2026, inclusive (the "Class Period"), have until Tuesday, August 4, 2026 to seek appointment as lead plain…
SAN FRANCISCO, July 7, 2026 /PRNewswire/ -- On February 20, 2026, GRAIL, Inc. (NASDAQ:GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to…
A securities fraud class action lawsuit has been filed on behalf of GRAIL investors after its stock plummeted 50% because GRAIL allegedly misled investors relating to GRAIL's NHS-Galleri cancer trial, potentially violating federal securities laws.NEW YORK, July 7, 2026 /PRNewswire/ -- Leading secur…
